Dyslipidemia
Conditions
Interventions
Ginsenoside intervention group:Take 3 ginsenoside capsules daily for 8 weeks
control group:Take 3 placebo capsules daily for 8 weeks
Sponsors
School of Public Health, Southern Medical University
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age 30-70 years old; (2) dyslipidemia: fasting serum TC = 5.2 mmol/L (200 mg/dL), LDL-C = 3.4 mmol/L (130 mg/dL); (3)BMI:18.5kg/?=BMI=30kg/?; (4) permanent residents of Guangzhou; (5) Regular living and eating, stable weight in the past three months; (6) Voluntarily fill in the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Currently taking or having taken any drugs that affect blood lipids, such as statins, aspirin, etc., in the past six months; (2) Currently taking or having taken any ginsenosides or ginseng Chinese medicines or dietary supplements in the past 3 months; (3) In the past 3 months, they have taken hypoglycemic drugs, glucocorticoids, diuretics, ß receptor blockers, aspirin and other drugs; (3) Suffering from serious chronic diseases, including stroke, myocardial infarction, stroke and other cardiovascular and cerebrovascular diseases, tumors, etc.; (4) Women who are pregnant, planning to become pregnant or breastfeeding; (5) Have had surgery in the past 3 months or need surgery in the next six months; (6) Have suffered from serious acute and chronic infectious diseases at present or within one month; (7) The baseline safety evaluation index is unqualified: (1) Obvious abnormal liver function: ALT and AST exceed the upper limit of normal by 3 times (male: =120 U/L, female: =90U/L); (2) Obvious abnormal renal function: serum creatinine exceeds the upper limit of normal by 1.5 times (male: =156µmol/L, female: =126µmol/L) or serum urea nitrogen =35.7mmol/L; (3) Severe diabetes: fasting blood glucose = 11.1 mmol/l; (8) Other investigators who deem it inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total cholesterol;ApoA1;ApoB; | — |
Secondary
| Measure | Time frame |
|---|---|
| Low density lipoprotein cholesterol;triglyceride;High density lipoprotein cholesterol;Fasting insulin;GLU; | — |
Countries
China
Contacts
Public ContactZha Longying
School of Public Health, Southern Medical University
Outcome results
None listed